Clinical trial

PDR001 + Panobinostat for Melanoma and NSCLC

NCT03982134

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2019-09-01

PhasePHASE1

Study timeline

Study start (estimated)2019-09-01Date precision: month

Registry last updated2019-10-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Melanomaunresolved

Non Small Cell Lung Cancerunresolved

Interventions

PDR001DRUG

PanobinostatDRUG · verified · RxNorm: panobinostat

Sponsors & collaborators

Muhammad Furqanlead sponsor

Novartis Pharmaceuticalscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03982134 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.